Status:
COMPLETED
Aripiprazole to Reduce Cocaine Relapse
Lead Sponsor:
Craig Rush
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Cocaine-Related Disorders
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
Despite the many behavioral and cognitive treatment therapies that exist for cocaine addiction, individuals who complete cocaine abuse treatment are still at high risk for relapsing. Aripiprazole, a m...
Detailed Description
Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Cocaine abusers often report that upon attempting to demonstrate control over the drug by only...
Eligibility Criteria
Inclusion
- Meets DSM-IV diagnostic criteria for cocaine dependence
- Current cocaine use at study entry, as determined by a urine screen
- Body Mass Index of less than 30
- ECG results within normal limits
- If female, willing to use contraception throughout the study
Exclusion
- Meets DSM-IV diagnostic criteria for dependence on any drugs other than cocaine or nicotine
- Currently seeking treatment for substance abuse
- Current or past serious illness, including impaired heart function, seizures, head trauma, or central nervous system tumors
- A family history of heart disease or seizures
- Current or past psychiatric disorder, other than substance abuse
- Pregnant
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00276874
Start Date
January 1 2006
End Date
January 1 2012
Last Update
April 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kentucky
Lexington, Kentucky, United States, 40506